VIR-2482 / Vir Biotech - LARVOL DELTA

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA). (PubMed, Clin Infect Dis) - "VIR-2482 1200 mg IM was well tolerated but did not significantly prevent protocol-defined ILI. Secondary endpoint analyses suggest this dose may have reduced influenza A illness."

Journal • Infectious Disease • Influenza • Respiratory Diseases

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness. (PubMed, Antimicrob Agents Chemother) - P1 | "The safety, tolerability, and pharmacokinetic profile of VIR-2482 at doses up to 1,800 mg supported its further investigation as a long-acting antibody for the prevention of influenza A illness. This study has been registered at ClinicalTrials.gov under identifier NCT04033406."

Clinical • Journal • P1 data • PK/PD data • Infectious Disease • Influenza • Respiratory Diseases

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A (clinicaltrials.gov) - P2 | N=2985 | Terminated | Sponsor: Vir Biotechnology, Inc. | Trial completion date: Jul 2024 ➔ Aug 2023 | Active, not recruiting ➔ Terminated; VIR-2482 did not achieve its primary efficacy endpoint in the prevention of seasonal Influenza A illness via intramuscular administration.

Trial completion date • Trial termination • Infectious Disease • Influenza • Respiratory Diseases

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A (clinicaltrials.gov) - P2 | N=3000 | Active, not recruiting | Sponsor: Vir Biotechnology, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A (clinicaltrials.gov) - P2 | N=3000 | Recruiting | Sponsor: Vir Biotechnology, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A (clinicaltrials.gov) - P2 | N=3000 | Not yet recruiting | Sponsor: Vir Biotechnology, Inc.

New P2 trial • Infectious Disease • Influenza • Respiratory Diseases

Study of VIR-2482 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=100 | Completed | Sponsor: Vir Biotechnology, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Respiratory Diseases

Study of VIR-2482 in Healthy Volunteers (clinicaltrials.gov) - P1; N=100; Active, not recruiting; Sponsor: Vir Biotechnology, Inc.; Enrolling by invitation ➔ Active, not recruiting; Phase classification: P1/2 ➔ P1; N=2860 ➔ 100; Trial primary completion date: Dec 2020 ➔ Nov 2021

Clinical • Enrollment change • Enrollment closed • Phase classification • Trial primary completion date • Infectious Disease • Respiratory Diseases

Study of VIR-2482 in Healthy Volunteers (clinicaltrials.gov) - P1/2; N=2860; Enrolling by invitation; Sponsor: Vir Biotechnology, Inc.; Active, not recruiting ➔ Enrolling by invitation

Clinical • Enrollment open • Infectious Disease

[VIRTUAL] VIR-2482: A potent and broadly neutralizing antibody for the prophylaxis of influenza A illness (IDWeek 2020) - "The attributes of potency, broad recognition of a highly conserved epitope, retention of high-level effector functions in addition to half-life extension support the development of VIR-2482 as a universal prophylactic for influenza A illness."

Infectious Disease

[VIRTUAL] Preliminary safety and pharmacokinetic profile of VIR-2482: a monoclonal antibody for the prevention of influenza A illness (IDWeek 2020) - "Based on available data, VIR-2482 has been well tolerated following single IM doses of up to 1800 mg in healthy subjects. The preliminary PK profile of VIR-2482 enables once per season dosing. Overall, these data support initiation of a Phase 2 study to evaluate efficacy of VIR-2482 for the prevention of influenza A illness."

Clinical • PK/PD data • Infectious Disease

[VIRTUAL] VIR2482: a potent and broadly neutralizing antibody for the prophylaxis of influenza A illness (ECCMID 2020) - No abstract available

Infectious Disease

Study of VIR-2482 in Healthy Volunteers (clinicaltrials.gov) - P1/2; N=2860; Active, not recruiting; Sponsor: Vir Biotechnology, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease

Study of VIR-2482 in Healthy Volunteers (clinicaltrials.gov) - P1/2; N=2860; Recruiting; Sponsor: Vir Biotechnology, Inc.; Not yet recruiting ➔ Recruiting; Trial completion date: May 2021 ➔ Jan 2022

Clinical • Enrollment open • Trial completion date